|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 700 THIRTEENTH STREET, NW |
Address2 | SUITE 525 |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | STAMFORD |
State | CT |
Zip Code | 06910 |
Country | USA |
|
5. Senate ID# 81214-12
|
||||||||
|
6. House ID# 362800000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: BURT ROSEN VP, FEDERAL GOVERNMENT AFFAIRS |
Date | 04/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
S 301 - Physician Payments Sunshine Act of 2009
HR 1191/S 1336 - Safe Drug Disposal Act of 2009
HR 1260/S 515 & 610 - Patent Reform Act of 2009
HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 1359/S 1292 - Secure and Responsible Drug Disposal Act of 2009
HR 1427/S 726 - Promoting Innovation and Access to Life-Saving Medicine Act
HR 1548 - Pathway for Biosimilars Act
HR 1706/S 369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009
HR 3200/S 1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009
HR 3590 - Patient Protection and Affordable Care Act
HR 3962 - Affordable Health Care for America Act
HR 4872 - Health Care and Education Reconciliation Act of 2010
HR 4956 - Stop Oxy Abuse Act of 2010
HR 756 - National Pain Care Policy Act of 2009
HR 5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010
HR 5809/S 3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010
HR 6165/S 4018 - Life Sciences Jobs and Investment Act of 2010
Anti- counterfeiting legislation concerning drugs (pedigree)
Biosimilar Drugs
Disposal of Drugs
Drug Reimportation
Healthcare Reform
Hearings related to prescription drug abuse and prevention
Life sciences research tax credit legislation
Patent Settlements
Pedigree Legislation
Prescription Drug User Fee Act reauthorization
RiskEvaluation and MitigationStrategies for controlled substances
Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Burt |
Rosen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S 301 - Physician Payments Sunshine Act of 2009
HR 1191/S 1336 - Safe Drug Disposal Act of 2009
HR 1260/S 515 & 610 - Patent Reform Act of 2009
HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 1359/S 1292 - Secure and Responsible Drug Disposal Act of 2009
HR 1427/S 726 - Promoting Innovation and Access to Life-Saving Medicine Act
HR 1548 - Pathway for Biosimilars Act
HR 1706/S 369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009
HR 3200/S 1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009
HR 3590 - Patient Protection and Affordable Care Act
HR 3962 - Affordable Health Care for America Act
HR 4872 - Health Care and Education Reconciliation Act of 2010
HR 4956 - Stop Oxy Abuse Act of 2010
HR 756 - National Pain Care Policy Act of 2009
HR 5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010
HR 5809/S 3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010
HR 6165/S 4018 - Life Sciences Jobs and Investment Act of 2010
Anti- counterfeiting legislation concerning drugs (pedigree)
Biosimilar Drugs
Disposal of Drugs
Drug Reimportation
Healthcare Reform
Hearings related to prescription drug abuse and prevention
Life sciences research tax credit legislation
Patent Settlements
Pedigree Legislation
Prescription Drug User Fee Act reauthorization
RiskEvaluation and MitigationStrategies for controlled substances
Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Burt |
Rosen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S 301 - Physician Payments Sunshine Act of 2009
HR 1191/S 1336 - Safe Drug Disposal Act of 2009
HR 1260/S 515 & 610 - Patent Reform Act of 2009
HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 1359/S 1292 - Secure and Responsible Drug Disposal Act of 2009
HR 1427/S 726 - Promoting Innovation and Access to Life-Saving Medicine Act
HR 1548 - Pathway for Biosimilars Act
HR 1706/S 369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009
HR 3200/S 1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009
HR 3590 - Patient Protection and Affordable Care Act
HR 3962 - Affordable Health Care for America Act
HR 4872 - Health Care and Education Reconciliation Act of 2010
HR 4956 - Stop Oxy Abuse Act of 2010
HR 756 - National Pain Care Policy Act of 2009
HR 5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010
HR 5809/S 3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010
HR 6165/S 4018 - Life Sciences Jobs and Investment Act of 2010
Anti- counterfeiting legislation concerning drugs (pedigree)
Biosimilar Drugs
Disposal of Drugs
Drug Reimportation
Healthcare Reform
Hearings related to prescription drug abuse and prevention
Life sciences research tax credit legislation
Patent Settlements
Pedigree Legislation
Prescription Drug User Fee Act reauthorization
RiskEvaluation and MitigationStrategies for controlled substances
Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Burt |
Rosen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S 301 - Physician Payments Sunshine Act of 2009
HR 1191/S 1336 - Safe Drug Disposal Act of 2009
HR 1260/S 515 & 610 - Patent Reform Act of 2009
HR 1298/S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009
HR 1359/S 1292 - Secure and Responsible Drug Disposal Act of 2009
HR 1427/S 726 - Promoting Innovation and Access to Life-Saving Medicine Act
HR 1548 - Pathway for Biosimilars Act
HR 1706/S 369 - Protecting Consumer Access to Generic Drugs Act of 2009/Preserve Access to Affordable Generics Act of 2009
HR 3200/S 1796 - America's Affordable Health Choices Act of 2009 / America's Healthy Future Act of 2009
HR 3590 - Patient Protection and Affordable Care Act
HR 3962 - Affordable Health Care for America Act
HR 4872 - Health Care and Education Reconciliation Act of 2010
HR 4956 - Stop Oxy Abuse Act of 2010
HR 756 - National Pain Care Policy Act of 2009
HR 5712 - Veterans', Seniors', and Children's Health Technical Corrections Act of 2010
HR 5809/S 3397 - Safe Drug Disposal/Secure and Responsible Drug Disposal Act of 2010
HR 6165/S 4018 - Life Sciences Jobs and Investment Act of 2010
Anti- counterfeiting legislation concerning drugs (pedigree)
Biosimilar Drugs
Disposal of Drugs
Drug Reimportation
Healthcare Reform
Hearings related to prescription drug abuse and prevention
Life sciences research tax credit legislation
Patent Settlements
Pedigree Legislation
Prescription Drug User Fee Act reauthorization
RiskEvaluation and MitigationStrategies for controlled substances
Tax on pharmaceutical companies (Senate Finance Committee draft of health care reform)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Burt |
Rosen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |